Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record.

An Evaluation of the Beta-1 Adrenergic Receptor Arg389Gly Polymorphism in Individuals with Heart Failure: A MERIT-HF Sub-Study

Open access
The MERIT-HF Study Group, White, Hazel L., de Boer, Rudolf A., Maqbool, Azhar, Greenwood, Darren, van Veldhuisen, Dirk J., Cuthbert, Richard, Ball, Stephen G., Hall, Alistair S., Balmforth, Anthony J. · 2003 · European Journal of Heart Failure

Abstract

Background: The Glycine389 variant of the beta-1 adrenergic receptor (β1AR) generates markedly less cAMP when stimulated in vitro than the more prevalent Arginine389 variant. Aims: The aim of this MERIT-HF sub-study was to ascertain whether this Glycine389 variant favourably influences outcome in heart failure similar to that observed with beta-blockers. Methods: We identified the genotype at amino acid 389 of the β1AR in 600 patients enrolled in the MERIT-HF study (UK and Dutch participants). A risk-ratio (RR) for each genotype was calculated using the combined endpoint of all cause mortality or hospitalisation (time to first event). A pharmacogenetic effect of this polymorphism was also sought by evaluating the effect of Metoprolol CR/XL on heart rate amongst the three genotypes. Results: The prevalence of the three genotypes was ArgArg 51.3%, ArgGly 40.2%, GlyGly 8.5%. The presence of the Gly allele was not associated with a significant benefit on the combined endpoint, RR=0.94; confidence intervals (CI), 0.69–1.29 (P=0.72). This is in contrast to the highly significant benefit of Metoprolol CR/XL observed in this sub-study population, RR=0.60; CI, 0.44–0.83 (P=0.002). No effect of the polymorphism was observed on the magnitude of heart rate reduction attained by Metoprolol CR/XL. Conclusion: In contrast to the benefits of beta-1 selective blockade, we have demonstrated that the Gly389 allele does not confer a significant mortality/morbidity benefit in heart failure patients. We have found no evidence of a pharmacogenetic effect of this biochemically functional polymorphism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1388-9842(03)00044-8

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 199

Metadata

Authors
The MERIT-HF Study Group, White, H. L., de Boer, R. A., Maqbool, A., Greenwood, D., van Veldhuisen, D. J., Cuthbert, R., Ball, S. G., Hall, A. S., & Balmforth, A. J.
Venue
European Journal of Heart Failure
Published
2003-08-01
Volume
5
Issue
4
Pages
463-468
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W1988225240
Cited by
199
References
0
FWCI
5.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Evaluation of the Beta-1 Adrenergic Receptor Arg389Gly Polymorphism in Individuals with Heart Failure: A MERIT-HF Sub-Study. https://app.cochat.ai/papers/10.1016/s1388-9842(03)00044-8
The paper
The MERIT-HF Study Group, White, H. L., de Boer, R. A., Maqbool, A., Greenwood, D., van Veldhuisen, D. J., Cuthbert, R., Ball, S. G., Hall, A. S., & Balmforth, A. J. (2003). An Evaluation of the Beta-1 Adrenergic Receptor Arg389Gly Polymorphism in Individuals with Heart Failure: A MERIT-HF Sub-Study. European Journal of Heart Failure. https://doi.org/10.1016/s1388-9842(03)00044-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.